Oculis (NASDAQ:OCS) Sees Strong Trading Volume – What’s Next?

Oculis Holding AG (NASDAQ:OCS) shares saw unusually-high trading volume on Wednesday . Approximately 70,058 shares traded hands during trading, a decline of 38% from the previous session’s volume of 112,347 shares.The stock last traded at $18.55 and had previously closed at $18.22.

Analyst Upgrades and Downgrades

OCS has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Oculis in a research note on Monday. Chardan Capital restated a “buy” rating and set a $28.00 price target on shares of Oculis in a research report on Tuesday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Oculis presently has a consensus rating of “Buy” and a consensus price target of $28.80.

Oculis Trading Up 13.1 %

The company’s 50 day moving average price is $16.41 and its two-hundred day moving average price is $13.91. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02. The stock has a market capitalization of $856.66 million, a PE ratio of -10.96 and a beta of -0.33.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.